GliomaCT-GlioHookNCT07725640
Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma
A study testing GlioHook device in people with Glioma and High-Grade Glioma (HGG), run by Batea Oncology at 3 sites in Spain.
Trial summary
This is a prospective, multicenter, single-arm, pilot clinical investigation, aimed at evaluating the safety and preliminary efficacy of the GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Glioma, High-Grade Glioma (HGG), Surgical Resection
- What is being tested?
- GlioHook device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 3 sitesSpain
- Study dates
- 30 Oct 2026to 30 Oct 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to provide written informed consent prior to the performance of any study-specific procedures.
- Age ≥18 and <70 years at the time of consent.
- Suspected newly diagnosed unifocal high-grade glioma, as suggested by preoperative MRI imaging.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Supratentorial and/or lobar tumor mass with a volume of less than 60cm3 as assessed by preoperative MRI.
- Patient scheduled to undergo surgical resection of the target brain lesion, with an expected extent of resection (EOR) ≥90% based on preoperative imaging and surgical planning and according to the investigator's criteria. The anticipated EOR should be verified intraoperatively using a validated available method depending on availability at study site, such as 5-aminolevulinic acid (5-ALA) fluorescence guidance, ultrasound, or MRI.
Show all 14Show fewer
- Candidate to receive standard-of-care treatment for newly diagnosed glioblastoma, according to current clinical practice and the investigator's judgment.
- Able to undergo contrast-enhanced MRI.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and study procedures and accessible for follow-up after completion of study treatment.
- For women of childbearing potential (WOCBP):
- Must have a negative serum or urine pregnancy test within 7 days prior to inclusion.
- Must not be pregnant or breastfeeding at the time of inclusion.
- Must agree to use a highly effective method of contraception during the entire study participation period and for at least 6 months after the last dose of temozolomide.
- Male and female patients of reproductive potential must agree to use highly effective contraceptive methods.
Who cannot join
- Life expectancy <3 months, as estimated by the investigator.
- Surgical resection cannot be assured or is considered not feasible or unsafe based on preoperative assessment.
- Tumor located in the posterior fossa or involving critical subcortical structures (e.g., midbrain, brainstem, ventricles, or basal ganglia), where safe surgical resection cannot be achieved.
- Presence of multifocal, bilateral, or recurrent tumor, or prior diagnosis of glioblastoma or other intracranial malignancy.
- Extent of tumor resection <90%. The EOR should be verified intraoperatively using a validated available method depending on availability at study site, such as 5-aminolevulinic acid (5-ALA) fluorescence guidance, ultrasound, or MRI. However, it is up to the neurosurgeon to assess, after reviewing the available data and the resection itself, whether the patient meets the criteria for implantation.
- Significant active or uncontrolled concurrent medical conditions, including but not limited to:
Show all 21Show fewer
- Active infection requiring systemic therapy,
- Symptomatic congestive heart failure,
- Unstable angina pectoris,
- Clinically significant cardiac arrhythmia,
- Uncontrolled hypertension,
- Severe pulmonary, hepatic, or renal disease,
- Psychiatric or social conditions that, in the opinion of the investigator, would interfere with study compliance or follow-up.
- Severe blood clotting disorders
- Known hypersensitivity to bovine-derived collagen or other components of the medical device.
- Contraindication to contrast-enhanced MRI, including known allergy to gadolinium or presence of non-MRI-compatible implants.
- Contraindication to receive radiotherapy or temozolomide, including prior cranial irradiation exceeding safe cumulative dose limits.
- Participation in another interventional clinical trial or use of an investigational product within 30 days prior to inclusion, or planned participation during this clinical investigation.
- Women who are pregnant or breastfeeding.
- Men or women of reproductive potential unwilling to use adequate contraception, as defined in the inclusion criteria.
- Inability or unwillingness to comply with clinical investigation procedures, follow-up schedule, or CIP requirements, as judged by the investigator.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Spain3 sites
Hospital Universitario Vall d'Hebron
Barcelona
Francisco Martínez Ricarte, MD
Francisco Martínez Ricarte, MD
Hospital HM Sanchinarro
Madrid
Juan Manuel Sepulveda Sánchez, MD
Juan Manuel Sepulveda Sánchez, MD
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela
Brais Rodríguez Botana, MD
Brais Rodríguez Botana, MD
About this study
This is a prospective, multicenter, single-arm, pilot clinical investigation, aimed at evaluating the safety and preliminary efficacy of the GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment.
GlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins, decreasing infiltration and focalizing the disease, while improving the effects of radiotherapy. Once implanted, GlioHook exerts a dual mechanism that combines tumour cell focalization and radiosensitization.
Read the detailed description
This clinical investigation is designed to evaluate the safety of the GlioHook implant, as measured by the occurrence of adverse events related to the GlioHook implant, as well as events involving the need for device removal, in patients with high-grade glioma undergoing surgical resection followed by standard of care. Preliminary efficacy of the medical device such as Progression-Free Survival (PFS) will also be assessed.
- Conditions
- Glioma, High-Grade Glioma (HGG), Surgical Resection
- Being tested
- GlioHook device
- Keywords
- Implant, High-Grade Glioma, Radiotherapy, Temozolomide
- Medical subject headings
- Glioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GlioHook deviceDevice
Also called GlioHook
GlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins.
| Study group | Role | What they receive |
|---|---|---|
| Experimental Arm | Experimental | GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment. Receives: Device: GlioHook device |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the safety of the GlioHook implant, as measured by the occurrence of adverse events related to the GlioHook implant, as well as events involving the need for device removal
Incidence of adverse events directly related to the implant of the device during follow-up, measured following NCI-CTCAE v6.0 guidelines, including events that involve the need of device removal.
Measured: 24 months
Secondary outcomes (7)
To evaluate the preliminary efficacy of GlioHook, measured as Progression-Free Survival (PFS), defined according to RANO 2.0 criteria.
PFS will be defined as the time from the date of surgery to the date of first documented disease progression or death from any cause, whichever occurs first.
Measured: 24 months
6 months Progression-Free Survival (PFS)
The 6-month PFS rate will also be reported. PFS will be defined as the time from the date of surgery to the date of first documented disease progression or death from any cause, whichever occurs first.
Measured: 6 months
Adjuvant Progression-Free Survival (PFS)
PFS will be also analyzed from start of adjuvant treatment. PFS will be defined as the time from the start of adjuvant treatment to the date of first documented disease progression or death from any cause, whichever occurs first.
Measured: 24 months.
To evaluate the preliminary efficacy of GlioHook, measured as Overall Survival (OS).
Overall Survival (OS). OS will be defined as time from date of surgery to date of death from any cause. OS will be also analyzed from start of adjuvant treatment.
Measured: 24 months
To evaluate changes in quality of life during the follow-up period (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30))
Percentage of patients maintaining stable or improved quality of life during the first 6 months of follow-up, compared with baseline.
Measured: 6 months
To evaluate changes in quality of life during the follow-up period (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Brain Cancer Module (EORTC QLQ-BN20))
Percentage of patients maintaining stable or improved quality of life during the first 6 months of follow-up, compared with baseline.
Measured: 6 months
To evaluate changes in neurological function during the follow-up period (Neurologic Assessment in Neuro-Oncology (NANO scale))
Percentage of patients maintaining stable or improved neurological function during the first 6 months of follow-up, compared with baseline.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Oct 2028 (estimated)
- Study completion30 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Batea Oncology
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Apices Soluciones S.L.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07725640
- Sponsor's protocol ID
- CT-GlioHook-2026-01
- Acronym
- CT-GlioHook
- Status last verified
- Jul 2026
- First submitted
- 21 Jul 2026
- Last updated
- 27 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma
- ClinicalTrials.gov ID
- NCT07725640
- Acronym / sponsor ID
- CT-GlioHook / CT-GlioHook-2026-01
- Conditions
- Glioma, High-Grade Glioma (HGG), Surgical Resection
- Keywords
- Implant, High-Grade Glioma, Radiotherapy, Temozolomide
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Batea OncologyIndustry (pharma, biotech, devices)
- Collaborators
- Apices Soluciones S.L.
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Oct 2028 (estimated)
- Study completion
- 30 Oct 2028 (estimated)
- First posted
- 24 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, multicenter, single-arm, pilot clinical investigation, aimed at evaluating the safety and preliminary efficacy of the GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment.
GlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins, decreasing infiltration and focalizing the disease, while improving the effects of radiotherapy. Once implanted, GlioHook exerts a dual mechanism that combines tumour cell focalization and radiosensitization.
Detailed description
This clinical investigation is designed to evaluate the safety of the GlioHook implant, as measured by the occurrence of adverse events related to the GlioHook implant, as well as events involving the need for device removal, in patients with high-grade glioma undergoing surgical resection followed by standard of care. Preliminary efficacy of the medical device such as Progression-Free Survival (PFS) will also be assessed.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental Arm | Experimental | Device: GlioHook deviceGlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Willing and able to provide written informed consent prior to the performance of any study-specific procedures.
- Age ≥18 and <70 years at the time of consent.
- Suspected newly diagnosed unifocal high-grade glioma, as suggested by preoperative MRI imaging.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Supratentorial and/or lobar tumor mass with a volume of less than 60cm3 as assessed by preoperative MRI.
Key exclusion criteria (21 listed)
- Life expectancy <3 months, as estimated by the investigator.
- Surgical resection cannot be assured or is considered not feasible or unsafe based on preoperative assessment.
- Tumor located in the posterior fossa or involving critical subcortical structures (e.g., midbrain, brainstem, ventricles, or basal ganglia), where safe surgical resection cannot be achieved.
- Presence of multifocal, bilateral, or recurrent tumor, or prior diagnosis of glioblastoma or other intracranial malignancy.
- Extent of tumor resection <90%. The EOR should be verified intraoperatively using a validated available method depending on availability at study site, such as 5-aminolevulinic acid (5-ALA) fluorescence guidance, ultrasound, or MRI. However, it is up to the neurosurgeon to assess, after reviewing the available data and the resection itself, whether the patient meets the criteria for implantation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GlioHook deviceAlso: GlioHookGlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins. | Device | Experimental Arm |
Primary outcome
To evaluate the safety of the GlioHook implant, as measured by the occurrence of adverse events related to the GlioHook implant, as well as events involving the need for device removal
Time frame: 24 months
Incidence of adverse events directly related to the implant of the device during follow-up, measured following NCI-CTCAE v6.0 guidelines, including events that involve the need of device removal.
7 secondary outcomes
To evaluate the preliminary efficacy of GlioHook, measured as Progression-Free Survival (PFS), defined according to RANO 2.0 criteria.
Time frame: 24 months
6 months Progression-Free Survival (PFS)
Time frame: 6 months
Adjuvant Progression-Free Survival (PFS)
Time frame: 24 months.
To evaluate the preliminary efficacy of GlioHook, measured as Overall Survival (OS).
Time frame: 24 months
To evaluate changes in quality of life during the follow-up period (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30))
Time frame: 6 months
To evaluate changes in quality of life during the follow-up period (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Brain Cancer Module (EORTC QLQ-BN20))
Time frame: 6 months
To evaluate changes in neurological function during the follow-up period (Neurologic Assessment in Neuro-Oncology (NANO scale))
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2026.
Related trials for Glioma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing GlioHook device in people with Glioma and High-Grade Glioma (HGG), run by Batea Oncology at 3 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact BATEA Oncology (0, contact@bateaoncology.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the safety of the GlioHook implant, as measured by the occurrence of adverse events related to the GlioHook implant, as well as events involving the need for device removal (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.